BR0314379A - Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase - Google Patents

Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase

Info

Publication number
BR0314379A
BR0314379A BR0314379A BR0314379A BR0314379A BR 0314379 A BR0314379 A BR 0314379A BR 0314379 A BR0314379 A BR 0314379A BR 0314379 A BR0314379 A BR 0314379A BR 0314379 A BR0314379 A BR 0314379A
Authority
BR
Brazil
Prior art keywords
phosphodiesterase inhibitors
quinazolinones
spirocondensed
compounds
spyrocondensed
Prior art date
Application number
BR0314379A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Bernardelli
Fabrice Vergne
Chrystelle Mendes
Pierre Gerard Ducrot
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0314379A publication Critical patent/BR0314379A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
BR0314379A 2002-09-17 2003-09-08 Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase BR0314379A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020292275 EP1400244A1 (en) 2002-09-17 2002-09-17 New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
PCT/IB2003/003965 WO2004026818A1 (en) 2002-09-17 2003-09-08 New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
BR0314379A true BR0314379A (pt) 2005-07-19

Family

ID=31896987

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314379A BR0314379A (pt) 2002-09-17 2003-09-08 Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase

Country Status (30)

Country Link
US (1) US7429598B2 (https=)
EP (2) EP1400244A1 (https=)
JP (1) JP2006501277A (https=)
KR (1) KR20050057371A (https=)
CN (1) CN1681507A (https=)
AP (1) AP2005003251A0 (https=)
AR (1) AR041271A1 (https=)
AU (1) AU2003259496A1 (https=)
BR (1) BR0314379A (https=)
CA (1) CA2499330C (https=)
CO (1) CO5540391A2 (https=)
CR (1) CR7728A (https=)
EA (1) EA200500312A1 (https=)
EC (1) ECSP055671A (https=)
GT (1) GT200300201A (https=)
HN (1) HN2003000285A (https=)
HR (1) HRP20050223A2 (https=)
IS (1) IS7700A (https=)
MA (1) MA27439A1 (https=)
MX (1) MXPA05002913A (https=)
NO (1) NO20051695L (https=)
OA (1) OA12924A (https=)
PA (1) PA8582801A1 (https=)
PE (1) PE20050073A1 (https=)
PL (1) PL375977A1 (https=)
TN (1) TNSN05073A1 (https=)
TW (1) TWI251590B (https=)
UY (1) UY27986A1 (https=)
WO (1) WO2004026818A1 (https=)
ZA (1) ZA200501381B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
EP1855686A1 (en) * 2005-03-01 2007-11-21 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0619126A2 (pt) 2005-12-02 2011-09-13 Pfizer Ltd derivados espirocìclicos, composição farmacêutica e usos dos mesmos
AU2007211840B2 (en) 2006-02-03 2012-03-01 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008119057A2 (en) * 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
ES2625817T3 (es) * 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) * 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
NZ609490A (en) 2010-10-21 2015-06-26 Biomarin Pharm Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ628054A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
CN112574202B (zh) * 2020-12-11 2021-11-09 台州学院 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用
IL318817A (en) 2022-08-18 2025-04-01 Mitodicure Gmbh Use of a therapeutic agent with PHOSPHODIESTERASE-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exercise intolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959685A (ja) * 1982-09-28 1984-04-05 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS5959865A (ja) * 1982-09-30 1984-04-05 Ube Ind Ltd 耐熱鋳鋼
US4906630A (en) * 1985-11-22 1990-03-06 Rorer Pharmaceutical Corporation Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds
US4666913A (en) * 1985-11-22 1987-05-19 William H. Rorer, Inc. Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses
US4764512A (en) * 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
US5102886A (en) 1990-10-12 1992-04-07 American Home Products Corporation 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO2000066560A1 (en) 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2002076953A1 (en) * 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6596167B2 (en) 2001-03-26 2003-07-22 Koch Membrane Systems, Inc. Hydrophilic hollow fiber ultrafiltration membranes that include a hydrophobic polymer and a method of making these membranes

Also Published As

Publication number Publication date
MA27439A1 (fr) 2005-07-01
US20040106631A1 (en) 2004-06-03
ECSP055671A (es) 2005-05-30
UY27986A1 (es) 2004-04-30
WO2004026818A1 (en) 2004-04-01
HRP20050223A2 (en) 2005-10-31
AU2003259496A1 (en) 2004-04-08
MXPA05002913A (es) 2005-05-27
US7429598B2 (en) 2008-09-30
IS7700A (is) 2005-02-17
EP1400244A1 (en) 2004-03-24
PL375977A1 (en) 2005-12-12
TWI251590B (en) 2006-03-21
CO5540391A2 (es) 2005-07-29
KR20050057371A (ko) 2005-06-16
HN2003000285A (es) 2004-11-23
JP2006501277A (ja) 2006-01-12
TNSN05073A1 (fr) 2007-05-14
TW200413333A (en) 2004-08-01
ZA200501381B (en) 2006-11-29
CA2499330C (en) 2009-04-28
AP2005003251A0 (en) 2005-03-31
PA8582801A1 (es) 2004-05-26
CA2499330A1 (en) 2004-04-01
GT200300201A (es) 2004-05-18
CR7728A (es) 2005-06-08
PE20050073A1 (es) 2005-02-28
OA12924A (en) 2006-10-13
CN1681507A (zh) 2005-10-12
NO20051695L (no) 2005-04-05
EP1542694A1 (en) 2005-06-22
AR041271A1 (es) 2005-05-11
EA200500312A1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR0108678A (pt) Novos compostos
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0419305B8 (pt) compostos inibidores de p38, composições farmacêuticas compreendendo os mesmos e usos dos referidos compostos na preparação de medicamentos
BR0111667A (pt) Novos compostos
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BR9812944A (pt) Inibidores bicìclicos da cinase
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BR0312464A (pt) Inibidores de tirosina quinases
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BR0314113A (pt) Derivados de amino propanol
BRPI0510410A (pt) compostos orgánicos
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/527, A61P 37/00, A61P 35/00

Ipc: A61K 31/527 (2011.01), A61P 37/00 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.